Celyad Oncology SA · EURONEXT:CYAD

Celyad Oncology SA — ASGCT 2018

17 slides from Celyad Oncology SA's conference presentation, May 2018

  1. Slide 1: Early signs of clinical activity of NKG2D CAR-T cell (CYAD-01) in AML patient

    Early signs of clinical activity of NKG2D CAR-T cell (CYAD-01) activity in AML patient Eytan Breman ASGCT May 2018

  2. Slide 2: Disclaimer

    Disclaimer In addition to historical facts or statements of current condition, this presentation contains forward-looking statements, including statements about the potential safety and feasibility of CYAD-01 cell therapy, including current and planned preclinical and clinical trials for Celyad’s pr

  3. Slide 3: Introduction – Major issues in cancer

    Introduction – Major issues in cancer • Genetic diversity among patients CAR T cells • Significant heterogeneity of cancer cells • Antigens present exclusively in the tumor - neoantigens • Downregulation of surfaced antigens as an escape mechanism http://www.nih.gov/about/discovery/chronicdiseases/c

  4. Slide 4: NKG2D binds to different known stress ligands expressed in a vast majority of tumors

    NKG2D binds to 8 different known stress ligands expressed in a vast majority of tumors Fernández-Messina L, et al, Front Immunol. 2012 Manuscript in preparation 4

  5. Slide 5: CYAD-01 activity in vitro

    CYAD-01 activity in vitro CYAD-01 CAR-T 200 SIGNAL 1 T o n ly 150 + P M A /Io n o 100 IF N - (n g /m l) 50 +H C T116 25 DAP10 +K 562 NKG2D SIGNAL 2 20 +M C F7 +TH P1 15 +H L60 10 + R a ji CD3ζ +O V C A R 3 5 +P A N C 1 0 M o c k T c e lls N K R 2 T c e lls 5

  6. Slide 6: CYAD-01 activity in vivo

    CYAD-01 activity in vivo OVARIAN CANCER LYMPHOMA CYAD-01 SIGNAL 1 CAR-T DAP10 NKG2D SIGNAL 2 Days Days Barber A, et al, Zhang T, et al, J Immunol. 2009 Can Res. 2007 CD3ζ MULTIPLE MYELOMA Barber A, et al, Gene Ther. 2011 6 Days

  7. Slide 7: CYAD-01: Phase I safety trial (CM-CS1)

    CYAD-01: Phase I safety trial (CM-CS1) 2015 2016 CYAD-01 Phase I Safety trial • Single administration, dose-escalation Phase I autologous CAR-T NKG2D study in patients with ▪ 1 administration AML and MM (Dana Farber). ▪ Low dose ▪ Hematological tumors • Strong safety profile, including no cell-relat

  8. Slide 8: THINK Study (THerapeutic Immunotherapy with NKG2D-based therapy)

    THINK Study (THerapeutic Immunotherapy with NKG2D-based therapy) o 3 dose levels (3x108,1x109 and 3x109) THINK Trial 1st CYAD-01 (D1) 2nd CYAD-01 (D2) Tumor 3rd CYAD-01 (D3) Washout period assessment D-35 D-21 D1 D15 D29 D43 D57 ▪ 3 administrations Apheresis End safety ▪ Primary Endpoint: Safety & T

  9. Slide 9: First observation of objective clinical response in AML

    First observation of objective clinical response in AML • 52 y male r/r AML • FLT3/NPMI mutations • Received chemotherapy and achieved CR1 but relapsed before allo-HSCT transplantation 9

  10. Slide 10: CYAD-01 functionality

    IF N - (n g /m L ) 0 .1 1 10 100 C Y A D -0 1 C Y A D -0 1 + K 5 6 2 C Y A D -0 1 + P A N C -1 CYAD-01 functionality LO D +A b N o A b C y to ly tic a c tiv ity (% ) 0 50 100 C Y A D -0 1 C Y A D -0 1 + C D 3 1 4 10

  11. Slide 11: Relapsed AML patient prior CYAD-01 CAR-T treatment

    Relapsed AML patient prior CYAD-01 CAR-T treatment 7% blasts Ligand expression prior to treatment 11 Sallman DA, et al, Hematologica, in press

  12. Slide 12: After CYAD-01 treatment: normal cellular phenotype & improved hematopoiesis

    After CYAD-01 treatment: normal cellular phenotype & improved hematopoiesis • No significant toxicities (grade 3 or above) • Platelets recover • Hgb recovery • BM blasts reduction • ANC recovery 12 Sallman DA, et al, Hematologica, in press

  13. Slide 13: SDF-1α levels measured over time

    SDF-1α levels measured over time • SDF-1α (CXCL12) is increased in direct relation to CYAD-01 infusions 800 • SDF-1α is an important agonist of CXCR4 C X C L 1 2 (S D F -1 ) 600 (p g /m l) 400 200 0 0 10 20 30 40 1 CYAD-01 2 3 T im e ( d a y s ) 13 Nagarsheth N, et al. Nature Rev Immunol. 2017

  14. Slide 14: RANTES levels measured over time

    RANTES levels measured over time • RANTES (CCL5) is increased in direct relation to CYAD-01 infusions • RANTES is a T lymphocyte chemotactic factor 300 • CCR5 expressed on monocytes and T cells R A N T E S (p g /m l) 200 100 0 0 10 20 30 40 2 3 T im e ( d a y s ) 1 CYAD-01 14 Nagarsheth N, et al. Na

  15. Slide 15: MCP1 (CCL2) levels measured over time

    MCP1 (CCL2) levels measured over time • MCP1 (CCL2) T lymphocyte chemotactic factor • Increase in direct relation to CYAD-01 infusions 500 400 M C P 1 (C C L 2 ) (p g /m l) 300 200 100 0 0 10 20 30 40 1 CYAD-01 2 3 T im e ( d a y s ) 15 Nagarsheth N, et al. Nature Rev Immunol. 2017

  16. Slide 16: Discussion/Conclusions

    Discussion/Conclusions • NKG2D CAR T cells (CYAD-01) can target a wide range of solid and liquid cancers in vitro and in preclinical models • An objective response in a patient with r/r AML in the early stages of the THINK trial. • Serum levels of SDF-1, RANTES and CCL2 modulate in line with dosing

  17. Slide 17: Thank you

    Thank you Contact: info@celyad.com BELGIUM USA Celyad SA Celyad Inc. Axis Business Park Seaport East Rue Edouard Belin, 2 2 Seaport Lane B-1435 Mont-Saint-Guibert Boston, MA. 02210 +32(0) 10 39 41 00 +1 857-990-6900

Celyad Oncology — ASGCT 2018 on 6ix